THERADIGM

What this means for you

This application is over — abandoned 24 Jun 2019. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

86622073

Mark type

Stylized text

Filed

07 May 2015

Published for opposition

29 Mar 2016

Abandoned

24 Jun 2019

Attorney of record

Christina L. Martini

Goods and services

• Class 001 — Chemicals: Biologics, namely cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances
• Class 005 — Pharmaceuticals: Biologics, namely cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, de-myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with the following symptoms: cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism
• Class 040 — Treatment of materials: Manufacturing of biologics, cells, scaffolds and matrices, and related biological materials
• Class 042 — Scientific and technological services: Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical consultation and research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, de myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism
• Class 044 — Medical, beauty and agricultural services: Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, de myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism

Owner

• COGNATE BIOSERVICES, INC., HANOVER, MD, US
• Theradigm, Inc., Bethesda, MD, US
• Theradigm, Inc., Bethesda, MD, US

Prosecution history

• 24 Jun 2019 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
• 24 Jun 2019 — ABANDONMENT - NO USE STATEMENT FILED
• 27 Nov 2018 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 26 Nov 2018 — SOU EXTENSION 5 GRANTED
• 15 Nov 2018 — SOU EXTENSION 5 FILED
• 26 Nov 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
• 15 Nov 2018 — SOU TEAS EXTENSION RECEIVED
• 11 May 2018 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 09 May 2018 — SOU EXTENSION 4 GRANTED
• 09 May 2018 — SOU EXTENSION 4 FILED
• 09 May 2018 — SOU TEAS EXTENSION RECEIVED
• 24 Nov 2017 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 22 Nov 2017 — SOU EXTENSION 3 GRANTED
• 22 Nov 2017 — SOU EXTENSION 3 FILED
• 22 Nov 2017 — SOU TEAS EXTENSION RECEIVED